MedPath

Cochicine Treatment for Post- Operative Pericardial Effusion

Phase 4
Completed
Conditions
Pericardial Effusion
Interventions
Drug: Placebo
Drug: Colchicines
Registration Number
NCT01266694
Lead Sponsor
French Cardiology Society
Brief Summary

Background: The incidence of asymptomatic pericardial effusion is high after cardiac surgery.

Objective: To assess whether colchicine is effective in reducing post operative pericardial effusion volume.

Design: Multicenter, randomized, double-blind, placebo-controlled study. Intervention : colchicine 1mg vs placebo, once daily for 14 days Setting :10 post operative cardiac rehabilitation centers. Patients: 200 patients at high risk of tamponade because of moderate to large persistent pericardial effusion (grade 2, 3 or 4 on a scale of 0 to 4 measured by echocardiography) more than 7 days after cardiac surgery.

Measurements: The main end point will be change in effusion grade after 14 days of treatment. Secondary endpoints include frequency of late cardiac tamponade.

Detailed Description

Clinically insignificant pericardial effusion is common after heart surgery with an incidence of 50 % to 85 % a few days after surgery Cardiac tamponade occurs in about 1-2 % of patients who undergo cardiac surgery and may develop slowly without clear-cut clinical signs. Most tamponade occurs more than 7 days after surgery which is a concern because, at that time, patients often have already been discharged from the hospital.

No study has ever shown the efficacy any drug for this condition.In particular, we published a study demonstrating the absence of efficacy of a non steroidal anti inflammatory drug (Meurin P, Tabet JY, Thabut G, et al.French Society of Cardiology. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. Ann Intern Med. 2010 Feb2;152(3):137-43) Cochicine is widely used to treat inflammatory pericarditis ; is it efficient to treat post operative pericardial effusions ? this is the question we want to answer to.

Design: Multicenter, randomized, double-blind, placebo-controlled study. Intervention : colchicine 1mg vs placebo, once daily for 14 days Setting :10 post operative cardiac rehabilitation centers. Patients: 200 patients at high risk of tamponade because of moderate to large persistent pericardial effusion (grade 2, 3 or 4 on a scale of 0 to 4 measured by echocardiography) more than 7 days after cardiac surgery.

Measurements: The main end point will be change in effusion grade after 14 days of treatment. Secondary endpoints include frequency of late cardiac tamponade.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
199
Inclusion Criteria
  • patients with recent cardiac surgery
  • admitted for cardiac rehabilitation
  • pericardial effusion > grade 2 (corresponds to a loculated effusion > 10 millimeters or a circumferential effusion of any size)on the first trans thoracic echocardiography performed more than 7 days after surgery
Exclusion Criteria
  • patients who do not give written consent to participate
  • pregnancy
  • colchicine allergy;
  • renal failure, which we define as a serum creatinine level > 250micromol/l or clairance < 30 ml/mn
  • heart transplantation,or correction of congenital heart anomalies cardiac surgery more than 30 days before their first trans thoracic echocardiography pericardial effusion that requires immediate drainage.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebopatients placebo controlled
CochicineColchicinesColchicine arm: patient receiving 1 mg per day for 14 days
Primary Outcome Measures
NameTimeMethod
change in effusion grade14 days
Secondary Outcome Measures
NameTimeMethod
frequency of late cardiac tamponade14 days
number of patients with at least a one-grade decrease in the effusion14 days
mean change in the width of the effusion measured in millimeters14 days
evolution of prespecified subgroups14 days

* patients with inflammatory syndrom : crp \> 30 mg/l

* patients receiving an anticoagulant

* patients with a post pericardiotomy syndrom

Trial Locations

Locations (10)

Bois Gibert

🇫🇷

Ballan Miré, France

Clinique Iris

🇫🇷

Marcy l'étoile, France

Centre Médical de Bligny

🇫🇷

Briis sous Forges, France

Clinique de Châtillon

🇫🇷

Châtillon, France

Hopital Corentin Celton

🇫🇷

Issy les moulineaux, France

Centre Dieulefit Santé

🇫🇷

Dieulefit, France

Clinique de la mitterie

🇫🇷

Lomme, France

Clinique les Grands Près

🇫🇷

Villeneuve Saint Denis, France

Centre Hospitalier Loire Vendée Océan

🇫🇷

Machecoul, France

Maison du mineur

🇫🇷

Vence, France

© Copyright 2025. All Rights Reserved by MedPath